- Take Action
- Take Action
Translational metastasis researchers and clinicians of the Metastasis Research Society have partnered with patient advocates of METAvivor Research and Support Inc. and clinicians from the Sentinel Node Oncology Foundation to create a one-of-a-kind conference and webinar series meant to engage researchers, clinicians, and patients together in metastasis research to improve stage IV metastatic cancer patient outcomes and quality of life. Year 1 of the project focused on metastatic breast cancer specifically (2017-2018) and year 2 has been expanded to continue focus on metastatic breast cancer but also include all metastatic cancer types (2018-2019).
Register below for the METAvivor/MRS Metastatic Cancer Stakeholder Engagement Conference on June 7 and 8, 2019 at the Lineberger Cancer Center at the University of North Carolina, Chapel Hill. Once registered, click here to book your room at the Courtyard by Marriott Chapel Hill.
A limited number of patient travel grants are available. Please contact [email protected] for an application.
Friday, June 7, 2019 - Conference Check-In 7:30 am - 8:15 am
Conference: 8:15 - 4:00 pm - Lunch and Breaks Included
Saturday, June 8, 2019 - Conference Check-In 8:00 am - 8:30 am
Conference: 8:30 am - 3:00 pm - Lunch and Breaks Included
PCORI Conference Room Block
Courtyard Chapel Hill for $129 USD per night
Room Block Start Date: Thursday, June 6, 2019 - Room Block End Date: Saturday, June 8, 2019
Last Day to Book: Monday, May 6, 2019
Book your group rate for PCORI Conference Room Block
Despite decades of cancer research, cancer metastasis (the spread of cancer from the primary site throughout the body) still causes approximately 90% of all cancer-related deaths worldwide and in the U.S. specifically (American Cancer Society and World Health Organization). There is no cure for metastatic cancer of any type.
Translational metastasis researchers and clinicians of the Metastasis Research Society have partnered with patient advocates of METAvivor Research and Support Inc. and clinicians from the Sentinel Node Oncology Foundation to create a one-of-a-kind conference and webinar series meant to engage researchers, clinicians, and patients together in metastasis research to improve stage IV metastatic cancer patient outcomes and quality of life. Year 1 of the project focused on metastatic breast cancer specifically (2017-2018) and year 2 has been expanded to continue focus on metastatic breast cancer but also include all metastatic cancer types (2018-2019). More information on year 2 can be found here.
1. Engage and educate stakeholders (patients, clinicians, researchers) in translational metastasis research and clinical comparative effectiveness research (CER). CER compares the benefits and harms of different treatment options or interventions that are already available to improve patient outcomes and quality of life relatively quickly. 2. Set research priorities for translational metastatic breast cancer research (a path forward for new treatments). 3. Set priorities for metastatic breast cancer clinical comparative effectiveness research (CER - a path forward for existing therapies) 4. Develop a sustainable model for patient engagement in metastasis research to engage key stakeholders in cancer metastasis to strengthen and advance patient-centered metastasis research from basic translational research through clinical comparative effectiveness research (CER). CER compares the use of existing therapies to improve patient outcomes relatively quickly.
Project collaborators include: translational metastasis researchers and clinicians of the Metastasis Research Society (MRS), patients/patient advocates of METAvivor Research and Support Inc. (project lead), and clinicians of the Sentinel Node Oncology Foundation (SNOF, project partner).
Welcome to the Metastatic Breast Cancer Engagement Conference (June 22-23, 2018)
Conference organizers (the Metastasis Research Society and METAvivor Research and Support Inc.) invite key stakeholders in breast cancer metastasis (MBC) research and treatment to join us for this novel engagement conference June 22-23, 2018. The two-day conference, located in the Stabile Research Building of the H. Lee Moffitt Cancer Center in Tampa, FL will accommodate 250 stakeholders in both lecture-style seating and in roundtable discussion groups.
Registration and Accomodations (REGISTRATION CLOSED JUNE 1, 2018)
$25 registration fee includes (lunch, dinner, etc.), and to register. Registrants can reserve rooms at three discounted locations within 1.5 miles of the conference venue. More information on accomodations here.
Agenda and Speakers
The agenda includes: sessions highlighting current advances in translational research and clinical MBC treatment, discussions to identify top MBC patient-desired outcomes, discussion and identification of top translational and clinical MBC research priorities addressing patient-desired outcomes, including the creation of specific clinical comparative effectiveness research questions, networking events, an educational session on resources for stakeholders, and discussions for identifying top barriers to stakeholder engagement in MBC research.
Click to view the full program book
Patients Included Accreditation:
This conference has been accredited for Patients Included status.
View our full Patients Included information sheet
Conference Continuing Education Learning Objectives
Housing and Meals
Conference registration will include snack/drink breaks, lunch, and dinner on the 22nd, and snack/drink breaks and lunch on the 23rd. The conference concludes before dinner. Breakfast is not included as nearly all hotels within 5 miles of the conference venue offer a complimentary breakfast. However, we will offer coffee, orange juice, and water in the mornings.
You are responsible for reserving and paying for your travel and lodging. Please click here to view a list of possible nearby hotel accommodations. Patients in need may apply for a limited number of patient support stipends to help cover these expenses here.
Those participating in the Metastatic Breast Cancer conference will be asked to fill out a brief pre- and post-conference survey so that organizers can evaluate the achievement of our goals and report this evaluation anonymously to our funding source, a Patient-Centered Outcomes Research Institute (PCORI) Eugene Washington PCORI Engagement Award (6102-MRS). Registrants for the conference will also be asked to vote on top translational and clinical metastatic breast cancer research topics in a separate very brief survey. The survey will be anonymous, and results will be used to rank national research priorities for discussion at the conference in June. Top priorities will later be published and shared publicly.
This conference was organized by members of the Metastasis Research Society and collaborating partners, METAvivor Research and Support Inc. (project subcontractor), and the Sentinel Node Oncology Foundation (SNOF, project partner - Cancer Metastasis logo).
This conference was funded through a Patient-Centered Outcomes Research Institute (PCORI) Eugene Washington PCORI Engagement Award (6102-MRS). The conference venue space was kindly donated by the H. Lee Moffitt Cancer Center in partnership with the MRS.
Registration for the MBC Engagement Conference has closed.
Click HERE for conference/webinar recordings and HERE for information on the next 2019 engagement conference.
Webinar 1: (MBC patient panel discussion)
October 18, 2017 at 1:00 PM ET
Webinar 2: (Translational MBC researcher panel discussion)
November 13, 2017 at 4:30 PM ET
Webinar 3: (MBC Oncologist Panel Discussion)
December 13, 2017 at 7:30PM ET
Metastatic Breast Cancer Engagement Conference:
June 22-23, 2018
2018 Conference Venue
H. Lee Moffitt Cancer Center, Tampa, Florida